ClarivateNYSE: CLVT

Clarivate NYSE: CLVT may not be the cheapest AI stock worth buying, but it is inexpensive and set up to rebound strongly over the next few quarters. Trading at a mere 7.5x its earnings outlook for 2025, it is a super-deep value compared to leading AI plays, and the estimates for earnings growth underestimate the company's potential.

New report highlights challenges and opportunities in resilient MedTech industry LONDON , July 2, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the release of the MedTech Trends to Watch 2024 report, the second installment in a two-part series offering a predictive analysis of emerging trends shaping the MedTech industry. Highlighting both challenges—such as economic uncertainty, regulatory shifts and fragile supply chains—and opportunities such as the rise of ambulatory surgical centers and AI in MedTech, the report provides a comprehensive outlook on industry trajectory.

LONDON , June 27, 2024 /PRNewswire/ --  Clarivate Plc  (NYSE:CLVT), a leading global provider of transformative intelligence, today released a Global Research Report from the Institute for Scientific Information (ISI)™. The report integrates and interprets multiple data sources from across Clarivate™ portfolios to highlight the academic and societal benefits of the rapidly evolving landscape of digital health.

Enabling users to save time and reduce risks in the IP filing and prosecution process LONDON , June 24, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today launched the IP Collaboration Hub™ at the 2024 Clarivate Ignite conference held in San Diego, U.S. The new solution integrates with Clarivate IP management systems (IPMS) to provide a central hub for collaborating with local agents worldwide. The IP Collaboration Hub enables users to save time and reduce risks in the IP filing and prosecution process by providing a portal for instructors and local agents to collaborate and exchange information, while automatically docketing everything in the IPMS.

Adds Emerging Sources Citation Index™ for a simplified and unified category view LONDON , June 20, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released the 2024 update to the Journal Citation Reports™ (JCR™). The reports provide an essential and comprehensive resource of high-quality journals, ranked by field to enable academic institutions, researchers and publishers to gauge the significance of journals in the global research landscape.

Emerging standouts set to transform drug discovery and development, revolutionize cancer treatment, and capture big pharma interest highlighted in third annual report LONDON , June 19, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its annual Companies to Watch report, highlighting seven innovative companies revolutionizing drug discovery and development. These companies are advancing antibody-drug conjugates (ADCs) to deliver highly targeted cancer treatments with minimal side effects.

Insights from the new InCites Benchmarking & Analytics module support strategic investment and demonstrate impact LONDON , June 4, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today launched Research Horizon Navigator™, a powerful new AI-native module within InCites Benchmarking & Analytics™ that highlights emerging research topics where future breakthroughs are likely to occur. Academics, funding agencies, government research organizations and research strategists will be able to identify new research trends and determine the most impactful areas for future investments and strategies.

Strategic collaboration enhances insight into patient demographics and behaviors, enabling analytical precision in addressing population health outcomes LONDON, May 31, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced a strategic partnership with HealthWise Data, a leading healthcare data and analytics firm bridging the gap between clinical outcomes and Social Determinants of Health (SDoH) domains. The collaboration integrates SDoH attributes into the Clarivate Real-World Data repository, offering comprehensive patient insights and enabling life science, healthcare and research professionals to enhance patient outcomes and healthcare equity.

LONDON , May 30, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT; CLVT PR A) ("Clarivate"), a leading global provider of transformative intelligence, announced today that its 5.25% Series A Mandatory Convertible Preferred Shares (the "Preferred Shares"), will automatically and mandatorily convert into ordinary shares of Clarivate on June 3, 2024 (the "Conversion Date"). The mandatory conversion rate for each Preferred Share will be 3.8462 ordinary shares of Clarivate.